John L. LaMattina net worth and biography

John LaMattina Biography and Net Worth

Director of Ligand Pharmaceuticals

John L. LaMattina, Ph.D., has served as a member of our board since February 2011. He spent 30 years at Pfizer Inc. with his last position starting in 2004 as President, Pfizer Global R&D. Dr. LaMattina began his career at Pfizer as a medicinal chemist in 1977. During his career, he was appointed to various positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998, Senior Vice President of Worldwide Development in 1999. Dr. LaMattina graduated with cum laude honors from Boston College with a B.S. in Chemistry. He received a Ph.D. from the University of New Hampshire in Organic Chemistry and subsequently was at Princeton University in the National Institutes of Health Postdoctoral Fellowship program. Dr. LaMattina is currently a senior advisor and board member at PureTech Health and serves on the boards of directors of Immunome, Inc., a publicly-traded biopharmaceutical company, and several privately-held biopharmaceutical companies. From 2013 until May 2020, Dr. LaMattina served on the board of directors of Zafgen, Inc., a publicly-traded biotechnology company, until its acquisition by Chondrial Therapeutics, Inc. and subsequent name change to Larimar Therapeutics, Inc. Dr. LaMattina also serves on the scientific advisory board of Frequency Therapeutics, a publicly-trade biotechnology company. Dr. LaMattina is a contributing writer to Forbes magazine.

What is John L. LaMattina's net worth?: The estimated net worth of John L. LaMattina is at least $2.85 million as of November 27th, 2024. Dr. LaMattina owns 29,515 shares of Ligand Pharmaceuticals stock worth more than $2,853,215 as of April 8th. This net worth evaluation does not reflect any other investments that Dr. LaMattina may own. Learn More about John L. LaMattina's net worth.
How do I contact John L. LaMattina?: The corporate mailing address for Dr. LaMattina and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at investors@ligand.com. Learn More on John L. LaMattina's contact information.
Has John L. LaMattina been buying or selling shares of Ligand Pharmaceuticals?: John L. LaMattina has not been actively trading shares of Ligand Pharmaceuticals over the course of the past ninety days. Most recently, John L. Lamattina sold 2,406 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $123.65, for a transaction totalling $297,501.90. Following the completion of the sale, the director now directly owns 29,515 shares of the company's stock, valued at $3,649,529.75. Learn More on John L. LaMattina's trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Todd Davis (CEO), Octavio Espinoza (CFO), Matthew Foehr (COO), Nancy Gray (Director), John Higgins (CEO), John Kozarich (Director), John LaMattina (Director), Andrew Reardon (Chief Legal Officer), and Stephen Sabba (Director). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, Ligand Pharmaceuticals insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $243,475.00. During the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 86,526 shares worth more than $8,524,068.88. The most recent insider tranaction occured on March, 4th when CFO Octavio Espinoza sold 5,000 shares worth more than $575,150.00. Insiders at Ligand Pharmaceuticals own 5.9% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 3/4/2025.

John L. LaMattina Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/27/2024	Sell	2,406	$123.65	$297,501.90	29,515
9/4/2018	Sell	3,335	$254.96	$850,291.60	24,784
6/4/2018	Sell	4,000	$194.51	$778,040.00	24,956
3/5/2018	Sell	3,335	$160.90	$536,601.50	24,291

John L. LaMattina Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $96.67

$94.77

$102.70

50 Day Range

MA: $111.88

$96.67

$122.23

2 Week Range

Now: $96.67

$67.72

$129.90

Volume

159,976 shs

Average Volume

123,017 shs

Market Capitalization

$1.86 billion

P/E Ratio

38.51

Dividend Yield

N/A

Beta

1.07